Junshi Biosciences has invested in the University of Birmingham-founded cancer immunotherapy developer, building on a research collaboration deal.

Revitope Oncology, a US-based cancer therapeutics spinout of University of Birmingham, yesterday obtained $10m in equity funding from biopharmaceutical firm Junshi Biosciences. Junshi will take a 9.99% stake having already entered an up to $800m collaboration and licensing agreement with the spinout in June 2020, when Junshi first made a conditional commitment to invest $10m.…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.